RFX1 Antibody

What is RFX1 and why is it important in biomedical research?

RFX1 (Regulatory Factor X1) is an evolutionary conserved transcription factor that influences a wide range of cellular processes including cell cycle regulation, proliferation, differentiation, and apoptosis. It functions as a critical regulatory element by binding to specific DNA sequences and controlling the expression of various target genes . RFX1 is particularly important in research because it acts as a regulatory factor essential for MHC class II gene expression, binding to the X boxes of these genes. Additionally, it binds to an inverted repeat (ENH1) required for hepatitis B virus gene expression and to the most upstream element (alpha) of the RPL30 promoter . Recent studies have revealed its roles in cancer biology, making it a potential therapeutic target .

What types of RFX1 antibodies are commercially available for research?

Several types of RFX1 antibodies are available for research applications:

• Rabbit polyclonal antibodies, such as ab110927, which target synthetic peptides within the Human RFX1 protein (aa 200-250)

• Mouse monoclonal antibodies with various isotypes and epitope targets:

The selection of antibody depends on the specific application, species being studied, and the epitope region of interest.

What are the primary applications for RFX1 antibodies in molecular and cellular research?

RFX1 antibodies are utilized in several key research applications:

• Western Blotting (WB): For detecting and quantifying RFX1 protein in tissue or cell lysates. The predicted band size for RFX1 is approximately 104 kDa .

• Immunoprecipitation (IP): For isolating RFX1 protein complexes to study protein-protein interactions. Studies have demonstrated successful IP with anti-RFX1 antibodies at concentrations of 6μg/mg lysate .

• Immunofluorescence (IF): For visualizing the cellular and subcellular localization of RFX1. Research indicates that RFX1 is primarily localized in the nuclei of neurons and microglial cells .

• ELISA: For quantitative detection of RFX1 in solution .

• Co-immunostaining: For determining cell-type specific expression. Double-labeled immunofluorescent staining with cell-type markers like MAP2 (neurons) or CD11b (microglia) helps identify the cellular origin of RFX1 expression .

How should RFX1 antibodies be stored and handled to maintain activity?

For optimal antibody performance and longevity, follow these methodological guidelines:

• Storage temperature: Most RFX1 antibodies should be stored at -20°C for long-term preservation. Avoid repeated freeze-thaw cycles by aliquoting the antibody before freezing.

• Working dilutions: For applications like Western blotting, typical working dilutions range from 1:1000 to 1:5000. For immunofluorescence, dilutions of 1:100 to 1:500 are common. Always verify the optimal dilution for your specific application and antibody .

• Thawing: Thaw antibodies on ice and centrifuge briefly before opening to collect all material at the bottom of the tube.

• Handling: Use sterile techniques and avoid contamination. When pipetting, avoid creating bubbles that can denature proteins.

• Reconstitution: For lyophilized antibodies, reconstitute according to manufacturer's instructions using sterile buffers.

• Validation: Periodically test antibody performance with positive controls to ensure activity has not degraded over time.

How can researchers validate the specificity of RFX1 antibodies for their particular experimental system?

Validating antibody specificity is critical for reliable research outcomes. Implement these methodological approaches:

• Knockout/Knockdown Controls: Use RFX1 knockout or knockdown samples as negative controls. Commercial CRISPR/Cas9 knockout plasmids for RFX1 are available for both human (sc-403144) and mouse (sc-422661) models . Compare staining patterns or band detection between wild-type and knockout/knockdown samples.

• Competing Peptide Assays: Pre-incubate the antibody with the immunizing peptide before application to your sample. Specific binding should be blocked by the competing peptide.

• Multiple Antibody Validation: Use antibodies targeting different epitopes of RFX1 (such as those targeting regions 61-290, 301-324, or 931-967) . Consistent results across different antibodies increase confidence in specificity.

• Heterozygous Models: Utilize heterozygous Rfx1+/− models as intermediate controls, which should show reduced expression compared to wild-type .

• Western Blot Analysis: Confirm a single band of the expected molecular weight (104 kDa for RFX1) . Multiple or unexpected bands may indicate non-specific binding.

• Mass Spectrometry: For definitive validation, immunoprecipitate RFX1 and analyze by mass spectrometry to confirm antibody is capturing the intended protein.

What are the optimal protocols for detecting RFX1 in different neural cell types?

Research indicates RFX1 is expressed in specific neural cell populations with distinct protocols for optimal detection:

• Neuronal Detection:

  • Use double immunofluorescent staining with anti-RFX1 (1:5000 dilution) and neuronal marker MAP2

  • Perform nuclear counterstaining as RFX1 is predominantly nuclear in neurons

  • Confocal microscopy is recommended for precise subcellular localization

• Microglial Cell Detection:

  • Double-label with RFX1 antibody and microglial marker CD11b

  • Optimize fixation to preserve microglial morphology (4% paraformaldehyde for 20 minutes)

  • Note that RFX1 staining appears in microglial nuclei

• Astrocyte Analysis:

  • While RFX1 is generally absent in astrocytes, negative controls using GFAP costaining are valuable

  • This absence can serve as an internal control for antibody specificity

• Brain Region-Specific Detection:

  • Higher expression levels are observed in olfactory bulb, hippocampus, and cerebral cortex

  • Adjust antibody concentration according to expected expression level in different brain regions

• Quantification Methods:

  • For protein level quantification, normalize RFX1 band densities to actin in Western blots

  • For transcriptional analysis, use quantitative PCR with appropriate housekeeping genes (GAPDH, actin)

How do researchers address cross-reactivity issues when studying RFX family members?

The RFX family consists of several members with structural similarities that can complicate antibody specificity. Address cross-reactivity with these methodological approaches:

• Epitope Selection: Choose antibodies targeting unique regions of RFX1 not conserved in other family members. The epitope regions 200-250 and 301-324 tend to have greater specificity for RFX1 .

• Sequence Alignment Analysis: Before selecting an antibody, perform sequence alignment of RFX family members to identify regions with minimal homology.

• Multiple Antibody Validation: Use antibodies targeting different epitopes and compare results for consistency.

• Knockout Controls for Multiple RFX Factors: When available, use genetic models lacking specific RFX factors to confirm antibody specificity.

• Preabsorption Tests: Perform preabsorption tests with recombinant proteins of different RFX family members to identify potential cross-reactivity.

• Western Blot Molecular Weight Discrimination: RFX family members have different molecular weights, allowing differentiation by band size in Western blot:

  • RFX1: 104 kDa

  • RFX2: ~80 kDa

  • RFX3: ~82 kDa

  • RFX4: ~65-90 kDa (isoform dependent)

  • RFX5: ~65 kDa

• RNA-based Validation: Confirm protein expression patterns with RNA analysis techniques like RT-qPCR or RNA-seq to support antibody-based findings.

What considerations should be made when designing experiments to study RFX1's role in gene regulation?

RFX1 functions as a transcription factor with complex regulatory activities. Consider these methodological approaches when studying its role in gene regulation:

• Chromatin Immunoprecipitation (ChIP):

  • Use RFX1 antibodies validated for ChIP to identify DNA binding sites

  • Focus on known binding motifs including X boxes in MHC class II genes and ENH1 sequences in hepatitis B virus genes

  • Design primers for qPCR that flank predicted binding sites

• Reporter Assays:

  • Design luciferase reporter constructs containing RFX1 binding sites

  • Include mutated binding site controls to confirm specificity

  • Co-transfect with RFX1 expression vectors to assess transcriptional activation or repression

• Genetic Modification Approaches:

  • Utilize commercial CRISPR/Cas9 knockout plasmids (sc-403144 for human, sc-422661 for mouse) or HDR plasmids for gene editing

  • Consider CRISPR activation systems (sc-403144-ACT for human, sc-422661-ACT for mouse) to upregulate RFX1 expression

  • Remember complete knockout is embryonically lethal, so conditional or inducible systems may be necessary

• Protein-Protein Interaction Studies:

  • Immunoprecipitate RFX1 using validated antibodies (0.4μg/ml for Western blot of immunoprecipitate)

  • Identify interaction partners through mass spectrometry

  • Verify interactions through reciprocal co-immunoprecipitation

• Cell-Type Specific Analysis:

  • RFX1 shows differential expression across cell types (present in neurons and microglia, absent in astrocytes)

  • Design experiments accounting for this cell-type specificity

  • Consider cell sorting techniques when working with mixed populations

How can researchers accurately quantify changes in RFX1 expression in disease models?

Accurate quantification of RFX1 expression changes requires robust methodological approaches:

• Protein Quantification Methods:

  • Western Blot: Normalize RFX1 band densities to housekeeping proteins like actin

  • Use digital imaging and analysis software (e.g., ImageQuant) for densitometric analysis

  • Include concentration curves with recombinant standards for absolute quantification

• Transcript Level Analysis:

  • RT-qPCR: Design primers specific to RFX1, avoiding regions with significant homology to other RFX family members

  • Use multiple reference genes (GAPDH, actin) for normalization

  • Apply the comparative threshold cycle method for relative quantification

• Single-Cell Analysis:

  • Flow cytometry with fluorescently labeled RFX1 antibodies for cell-by-cell quantification

  • Single-cell RNA-seq to detect cell-specific expression changes

  • Imaging cytometry combining cellular morphology with expression quantification

• Spatial Analysis in Tissue:

  • Quantitative immunohistochemistry with digital image analysis

  • Laser capture microdissection combined with qPCR or proteomics

  • RNAscope for highly sensitive RNA detection with spatial context

• Disease Model Considerations:

  • Include appropriate time-course analysis as RFX1 may show dynamic changes during disease progression

  • Compare multiple disease models as RFX1 functions may be context-dependent

  • Consider both protein and transcript level analysis as post-transcriptional regulation may occur

What are common problems encountered when using RFX1 antibodies in Western blotting, and how can they be resolved?

Researchers may encounter several challenges when using RFX1 antibodies for Western blotting:

• Weak or Absent Signal:

  • Increase antibody concentration (try 1:1000 to 1:5000 range)

  • Extend primary antibody incubation time to overnight at 4°C

  • Enhance detection sensitivity with amplification systems

  • Increase protein loading (50-100μg total protein per lane)

  • Verify sample preparation preserves nuclear proteins (RFX1 is primarily nuclear)

• Multiple Bands or Background:

  • Increase blocking stringency (5% BSA or milk for 1-2 hours)

  • Add 0.1-0.3% Tween-20 to wash buffers

  • Decrease primary antibody concentration

  • Try alternative antibodies targeting different epitopes (61-290, 301-324, or 931-967)

  • Use freshly prepared samples to minimize protein degradation

• Incorrect Band Size:

  • Expected size for RFX1 is 104 kDa

  • Confirm using positive controls with known RFX1 expression

  • Consider post-translational modifications that may alter migration

  • Use protein ladders that accurately mark the 100-110 kDa range

• Inconsistent Results:

  • Standardize lysate preparation protocols

  • Normalize loading with housekeeping proteins (actin)

  • Quantify bands using densitometry software (e.g., ImageQuant)

  • Maintain consistent transfer conditions across experiments

• Methodological Optimizations:

  • For nuclear proteins like RFX1, optimize nuclear extraction protocols

  • Consider using gradient gels (4-12%) for better resolution of high molecular weight proteins

  • Test PVDF versus nitrocellulose membranes for optimal binding

What are the critical factors for successful immunoprecipitation experiments using RFX1 antibodies?

Successful immunoprecipitation of RFX1 requires attention to several methodological details:

• Antibody Selection and Concentration:

  • Use antibodies validated specifically for IP applications

  • Optimal concentration range: 6μg antibody per mg of lysate

  • Consider using a combination of antibodies targeting different epitopes for enhanced pull-down

• Lysate Preparation:

  • Use nuclear extraction protocols since RFX1 is predominantly nuclear

  • Include protease inhibitors to prevent degradation

  • DNase treatment may improve release of chromatin-bound RFX1

  • Adjust salt concentration (150-300mM NaCl) to maintain protein-protein interactions

• Immunoprecipitation Conditions:

  • Pre-clear lysate with protein A/G beads to reduce non-specific binding

  • Optimize antibody-lysate incubation time (4-16 hours at 4°C)

  • Use gentle rotation to maintain antibody-antigen interaction

  • Perform thorough washing (4-5 washes) while preserving specific interactions

• Elution and Detection:

  • Elute under native conditions if studying protein complexes

  • For Western blot detection, load 20% of IP material per lane

  • Use TrueBlot secondary antibodies to minimize detection of heavy/light chains

• Controls:

  • Include isotype-matched control antibodies

  • Incorporate input samples (5-10% of starting material)

  • Use RFX1-knockout or knockdown samples as negative controls

• Troubleshooting Tips:

  • If detecting associated proteins, cross-linking may stabilize transient interactions

  • Adjust detergent concentration to maintain protein-protein interactions

  • Consider IP-MS (mass spectrometry) for unbiased identification of binding partners

How can researchers optimize immunofluorescence staining with RFX1 antibodies in different tissue types?

Optimizing immunofluorescence staining for RFX1 requires tissue-specific considerations:

• Fixation Methods:

  • For brain tissue: 4% paraformaldehyde fixation preserves RFX1 antigenicity

  • For cultured cells: Test both paraformaldehyde and methanol fixation

  • Duration matters: Overfixation can mask epitopes (10-20 minutes optimal for most applications)

• Antigen Retrieval:

  • Heat-induced epitope retrieval (citrate buffer pH 6.0) may enhance nuclear antigen detection

  • For formalin-fixed tissues, more aggressive retrieval may be necessary

  • Enzymatic retrieval with proteinase K can be tested if heat methods fail

• Permeabilization:

  • Nuclear antigens like RFX1 require effective permeabilization

  • Try 0.1-0.3% Triton X-100 for 10-15 minutes

  • For cultured cells, 0.1% saponin may provide gentler permeabilization

• Blocking and Antibody Dilutions:

  • Block with 5-10% normal serum from the species of secondary antibody

  • Starting dilution ranges: 1:100 to 1:500 for immunofluorescence

  • Extend primary antibody incubation to overnight at 4°C for maximum sensitivity

• Double-Labeling Protocols:

  • For neuronal co-staining: Combine RFX1 antibody with MAP2

  • For microglial co-staining: Use CD11b marker

  • For negative control co-staining: Use GFAP (astrocyte marker)

• Signal Amplification:

  • Consider tyramide signal amplification for low-abundance detection

  • Fluorophore-conjugated secondary antibodies with bright, photostable dyes improve signal

  • Use mounting media with antifade properties to preserve fluorescence

• Imaging Considerations:

  • Confocal microscopy recommended for nuclear localization confirmation

  • Z-stack imaging to ensure complete capture of nuclear signal

  • Consistent exposure settings for quantitative comparisons

What approaches can resolve non-specific binding issues with RFX1 antibodies in immunohistochemistry?

Non-specific binding in immunohistochemistry can compromise research findings. Address these issues with systematic approaches:

• Antibody Validation:

  • Test multiple antibodies targeting different epitopes of RFX1

  • Compare staining patterns between antibodies

  • Verify specificity using heterozygous Rfx1+/− tissues with reduced expression

• Blocking Optimization:

  • Extend blocking time (1-2 hours at room temperature)

  • Test different blocking agents (BSA, normal serum, commercial blocking buffers)

  • Add 0.1-0.2% Tween-20 to blocking solutions to reduce hydrophobic interactions

• Antibody Dilution Series:

  • Perform titration experiments to identify optimal concentration

  • Too concentrated antibody often increases background

  • Extend incubation time with more dilute antibody solutions

• Control Experiments:

  • Include no-primary antibody controls

  • Use competing peptide controls where antibody is pre-incubated with immunizing peptide

  • If available, include RFX1 knockout tissue sections as negative controls

• Tissue-Specific Considerations:

  • Perfused tissue generally shows cleaner staining than immersion-fixed

  • Fresh frozen may preserve epitopes better than paraffin-embedded

  • Adjust protocols based on specific tissue requirements

• Cross-Reactivity Reduction:

  • Pre-absorb antibodies against tissue from knockout animals

  • Use highly cross-adsorbed secondary antibodies

  • Consider monoclonal antibodies for higher specificity

• Signal-to-Noise Enhancement:

  • Implement additional wash steps (5-6 washes of 10 minutes each)

  • Use avidin-biotin blocking for tissues with endogenous biotin

  • Block endogenous peroxidase activity thoroughly before antibody application

How can RFX1 antibodies be utilized to investigate its role in cancer biology?

RFX1 has emerging significance in cancer research, with antibodies playing a crucial role in investigating its functions:

• Expression Analysis Across Cancer Types:

  • Use Western blotting with RFX1 antibodies to compare expression levels between normal and cancerous tissues

  • Perform immunohistochemistry on tissue microarrays to assess expression across multiple cancer types

  • Quantify expression changes during cancer progression and correlation with patient outcomes

• Mechanistic Studies:

  • Employ ChIP-seq with RFX1 antibodies to identify cancer-specific binding sites

  • Combine with RNA-seq after RFX1 modulation to determine regulated genes

  • Study RFX1's impact on cell proliferation, apoptosis, and chemoresistance pathways

• Protein-Protein Interaction Networks:

  • Use immunoprecipitation with RFX1 antibodies followed by mass spectrometry

  • Identify cancer-specific interaction partners that may represent therapeutic targets

  • Verify interactions through reciprocal co-IP and proximity ligation assays

• Cancer Stem Cell Research:

  • Evaluate RFX1 expression in cancer stem cell populations using flow cytometry

  • Assess the impact of RFX1 modulation on stemness markers and chemoresistance

  • Study RFX1's role in sensitizing cancer stem cells to therapy

• Experimental Therapeutic Approaches:

  • Monitor RFX1 expression changes in response to treatments

  • Use inducible expression systems to modulate RFX1 levels

  • Combine with CRISPR activation or knockout approaches to study therapeutic potential

What methodological considerations are important when studying RFX1 expression in neurodegenerative disorders?

Investigating RFX1 in neurodegenerative contexts requires specific methodological considerations:

• Brain Region-Specific Analysis:

  • RFX1 shows differential expression across brain regions (higher in olfactory bulb, hippocampus, cerebral cortex)

  • Target analysis to disease-relevant regions (e.g., substantia nigra for Parkinson's, hippocampus for Alzheimer's)

  • Use precise microdissection techniques for region-specific extraction

• Cell Type-Specific Considerations:

  • RFX1 is expressed in neurons and microglia but absent in astrocytes

  • Design experiments considering cell-type specific expression

  • Use NeuN/MAP2 (neurons) and CD11b (microglia) co-staining for cell identification

• Animal Models:

  • Complete Rfx1 knockout is embryonically lethal

  • Use conditional knockouts in specific neuronal populations

  • Consider heterozygous models (Rfx1+/−) which are viable and show reduced expression

• Human Tissue Analysis:

  • Post-mortem interval significantly impacts protein preservation

  • Include age-matched controls and account for medication effects

  • Optimize fixation protocols to preserve nuclear antigens

• Functional Studies:

  • Investigate relationship between RFX1 and neuroinflammatory processes

  • Study impact on glutamate transporter type 3 regulation in neurodegeneration

  • Assess potential neuroprotective or detrimental effects through gene modulation

• Technical Considerations:

  • Nuclear extraction is critical as RFX1 is predominantly nuclear

  • Include appropriate controls for antibody specificity

  • Consider dual RNA-protein analysis from the same samples

How can researchers effectively use RFX1 antibodies in studying autoimmune conditions related to MHC class II dysregulation?

Given RFX1's role in regulating MHC class II genes , antibodies against RFX1 are valuable tools for investigating autoimmune conditions:

• Expression Analysis in Immune Cells:

  • Quantify RFX1 levels in various immune cell populations (B cells, dendritic cells, macrophages)

  • Compare expression between patients with autoimmune disorders and healthy controls

  • Correlate expression with disease activity and treatment response

• Chromatin Dynamics Studies:

  • Use ChIP with RFX1 antibodies to assess binding to MHC class II promoters in disease states

  • Combine with histone modification ChIP to understand epigenetic regulation

  • Compare binding patterns between patient-derived and control cells

• Transcriptional Complex Analysis:

  • Investigate RFX1 interactions with other transcription factors (CIITA, RFX5, RFXAP, RFXANK)

  • Use sequential ChIP (Re-ChIP) to identify co-occupancy at MHC class II promoters

  • Perform co-immunoprecipitation to detect altered complex formation in disease

• Functional Studies:

  • Modulate RFX1 levels using CRISPR systems and assess impact on MHC class II expression

  • Evaluate consequences for antigen presentation and T cell activation

  • Test potential therapeutic approaches targeting RFX1 regulation

• Single-Cell Analysis:

  • Use immunofluorescence to detect cell-specific RFX1 expression in affected tissues

  • Combine with MHC class II staining to correlate expression patterns

  • Implement flow cytometry for quantitative single-cell analysis

• Methodological Optimizations:

  • For inflammatory tissues, optimize antigen retrieval methods

  • Include multiple antibody controls due to potential cross-reactivity

  • Consider multiple epitope-targeting antibodies for confirmation

How can CRISPR-based approaches be combined with RFX1 antibodies for functional genomics studies?

Integrating CRISPR technology with RFX1 antibodies creates powerful research tools:

• CRISPR Knockout Validation:

  • Use commercial CRISPR/Cas9 knockout plasmids for RFX1 (sc-403144 for human, sc-422661 for mouse)

  • Confirm knockout efficiency with RFX1 antibodies via Western blot and immunofluorescence

  • Use knockout cells as negative controls for antibody validation

• Gene Editing Applications:

  • Utilize HDR plasmids (sc-403144-HDR for human, sc-422661-HDR for mouse) to introduce mutations

  • Apply RFX1 antibodies to assess effects on protein expression and localization

  • Perform ChIP-seq with RFX1 antibodies in edited cells to identify altered binding patterns

• Gene Activation Studies:

  • Implement CRISPR activation systems (sc-403144-ACT, sc-422661-ACT) to upregulate RFX1

  • Confirm overexpression using validated antibodies

  • Perform immunoprecipitation to identify new protein interactions in overexpression context

• Epitope Tagging:

  • Use CRISPR to insert epitope tags into endogenous RFX1

  • Compare commercial RFX1 antibodies with tag-specific antibodies

  • Develop dual detection strategies for enhanced specificity

• Inducible Systems:

  • Since complete knockout is embryonically lethal , create inducible Rfx1 knockout systems

  • Monitor expression dynamics using antibodies during induction time course

  • Study temporal aspects of RFX1 function through controlled expression

• Multiplex Approaches:

  • Combine CRISPR screens with RFX1 antibody-based detection methods

  • Create reporter cell lines with RFX1 target promoters

  • Develop high-throughput assays for RFX1 modulator screening

What are the methodological approaches for studying post-translational modifications of RFX1 using modified-specific antibodies?

Investigating post-translational modifications (PTMs) of RFX1 requires specialized approaches:

• Modification-Specific Antibody Selection:

  • Phospho-specific antibodies for known or predicted phosphorylation sites

  • Antibodies targeting acetylation, SUMOylation, or ubiquitination

  • Custom antibody development for novel modifications

• Enrichment Strategies:

  • Perform immunoprecipitation with general RFX1 antibodies followed by Western blotting with modification-specific antibodies

  • Use phosphatase inhibitors during sample preparation to preserve phosphorylation

  • Implement HDAC inhibitors to maintain acetylation states

• Validation Approaches:

  • Treatment with modifying enzymes (phosphatases, deacetylases) as negative controls

  • Use of stimuli known to induce specific modifications

  • Employ site-directed mutagenesis of PTM sites combined with antibody detection

• Mass Spectrometry Integration:

  • Immunoprecipitate RFX1 using validated antibodies

  • Perform MS analysis to identify and map modification sites

  • Develop targeted MS approaches for specific modifications

• Functional Analysis:

  • Correlate modifications with DNA binding capacity using ChIP

  • Assess impact on protein-protein interactions

  • Study modification changes during cellular processes (cell cycle, differentiation)

• Spatio-temporal Analysis:

  • Use immunofluorescence with modification-specific antibodies

  • Track dynamic changes in modifications following stimuli

  • Correlate with functional outcomes in different cellular contexts

How can single-cell analysis techniques be combined with RFX1 antibodies to understand cellular heterogeneity?

Integrating RFX1 antibodies with single-cell technologies provides insights into cellular heterogeneity:

• Flow Cytometry Applications:

  • Develop intracellular staining protocols for RFX1 detection

  • Combine with surface markers for cell type identification

  • Use fluorescence-activated cell sorting (FACS) to isolate RFX1-high and RFX1-low populations

• Mass Cytometry (CyTOF) Integration:

  • Label RFX1 antibodies with rare earth metals

  • Combine with 30+ other markers for comprehensive phenotyping

  • Create high-dimensional maps of RFX1 expression across cell populations

• Single-Cell Western Blotting:

  • Adapt RFX1 antibody protocols for microfluidic single-cell Western platforms

  • Quantify cell-to-cell variation in RFX1 expression

  • Correlate with other protein markers at single-cell resolution

• Imaging Mass Cytometry:

  • Apply metal-labeled RFX1 antibodies to tissue sections

  • Obtain spatial information alongside expression data

  • Analyze tissue microenvironment and cellular interactions

• Cellular Indexing of Transcriptomes and Epitopes (CITE-seq):

  • Conjugate RFX1 antibodies with oligonucleotide barcodes

  • Simultaneously measure surface proteins and transcriptomes

  • Correlate RFX1 protein levels with gene expression profiles

• Single-Cell Imaging:

  • Implement multiplexed immunofluorescence with RFX1 antibodies

  • Use computational analysis to quantify nuclear staining intensity

  • Apply machine learning for classification of expression patterns